{"id":816772,"date":"2025-02-24T10:39:33","date_gmt":"2025-02-24T15:39:33","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/biodexa-announces-allowance-of-u-s-patent-covering-oral-rapamycin-nanoparticle-preparations-erapa-and-use\/"},"modified":"2025-02-24T10:39:33","modified_gmt":"2025-02-24T15:39:33","slug":"biodexa-announces-allowance-of-u-s-patent-covering-oral-rapamycin-nanoparticle-preparations-erapa-and-use","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/biodexa-announces-allowance-of-u-s-patent-covering-oral-rapamycin-nanoparticle-preparations-erapa-and-use\/","title":{"rendered":"Biodexa Announces Allowance of U.S. Patent Covering  Oral Rapamycin Nanoparticle Preparations (\u201ceRapa\u201d) and Use"},"content":{"rendered":"<div class=\"mw_release\">\n<p>February 24, 2025<\/p>\n<p align=\"center\">\n        <strong>Biodexa Announces Allowance of U.S. Patent Covering <\/strong><br \/>\n        <br \/>\n        <strong>Oral Rapamycin Nanoparticle Preparations (\u201ceRapa\u201d) and Use<\/strong>\n      <\/p>\n<p align=\"center\">\n        <em>Biodexa plans to initiate a Phase 3 registrational study of eRapa in <\/em><br \/>\n        <br \/>\n        <em>Familial Adenomatous Polyposis (FAP) next quarter<\/em>\n      <\/p>\n<p align=\"justify\">Biodexa Pharmaceuticals PLC (\u201cBiodexa\u201d or the \u201cCompany\u201d)(Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, today announced that the U.S. Patent and Trademark Office allowed has U.S. patent application No. 17\/391.495 titled \u201cOral Rapamycin Nanoparticle Preparations and Use\u201d which was exclusively licensed to Biodexa by Rapamycin Holdings, Inc. d\/b\/a Emtora Biosciences, along with other patents, in a transaction which closed in April 2024. The patent is due to issue on March 4, 2025 and, in the absence of any patent term extensions, is expected to expire in March, 2034.<\/p>\n<p align=\"justify\">Stephen Stamp, CEO and CFO of Biodexa, commented \u201cThe FDA has already granted orphan drug designation for our most advanced program, eRapa in FAP which confers seven years market exclusivity from approval in the US. This patent provides a welcome additional layer of exclusivity for the novel eRapa drug formulation as we investigate additional indications.\u201d<\/p>\n<p>\n        <strong>About eRapa<\/strong>\n      <\/p>\n<p align=\"justify\">eRapa is a proprietary oral tablet formulation of rapamycin, also known as sirolimus. Rapamycin is an mTOR (<u>m<\/u>ammalian <u>T<\/u>arget <u>O<\/u>f <u>R<\/u>apamycin) inhibitor. mTOR has been shown to have a significant role in the signalling pathway that regulates cellular metabolism, growth and proliferation and is activated during tumorgenesis<sup>3<\/sup>. Importantly, mTOR has been shown to be over-expressed in FAP polyps \u2013 thereby underscoring the rationale for using a potent and safe mTOR inhibitor like eRapa to treat FAP. Rapamycin is approved in the US for organ rejection in renal transplantation as Rapamune\u00ae(Pfizer). Through the use of nanotechnology and pH sensitive polymers, eRapa is designed to address the poor bioavailability, variable pharmacokinetics and toxicity generally associated with the currently available forms of rapamycin. Compelling six month data from a Phase 2 study of eRapa in FAP were presented at Digestive Disease Week in April 2024 and 12 month data were presented at InSIGHT, Barcelona in June 2024. A registrational Phase 3 study in approximately 30 centers in the US and Europe is expected to begin recruitment next quarter. The Phase 3 program is substantially funded by a $17.0 million grant from the Cancer Prevention Research Institute of Texas (CPRIT) which has been matched by Company contributions of $8.5 million. <br \/><strong>The Cancer Prevention and Research Institute of Texas<\/strong><br \/>To date, CPRIT has awarded\u00a0$2.9 billion\u00a0in grants to\u00a0Texas\u00a0research institutions and organizations through its academic research, prevention and product development research programs. CPRIT has recruited 237 distinguished researchers, supported the establishment, expansion or relocation of 43 companies to\u00a0Texas\u00a0and generated over\u00a0$5.7 billion\u00a0in additional public and private investment. CPRIT funding has advanced scientific and clinical knowledge and provided 7.4 million life-saving cancer prevention and early detection services reaching Texans from all 254 counties. On\u00a0November 5, 2019,\u00a0Texas\u00a0voters overwhelmingly approved a constitutional amendment to provide an additional\u00a0$3 billion\u00a0to CPRIT for a total\u00a0$6 billion\u00a0investment in cancer research and prevention. Learn more at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=wC9hXDKk9XeXDBeuuqAOamuiBf5xKs4HG519v0C6t_n1Tngh6rGj8AQ12LS8NEbk6LAs-KtbzwiItoeOLt0Ibh_JFt2k1IYzBHNWfd5Kfro=\" rel=\"nofollow\" target=\"_blank\"><u>https:\/\/cprit.texas.gov\/<\/u><\/a>.<\/p>\n<p>\n        <strong>About Biodexa Pharmaceuticals PLC<\/strong>\n      <\/p>\n<p align=\"justify\">Biodexa Pharmaceuticals PLC (listed on NASDAQ: BDRX) is a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs. The Company\u2019s lead development programs include eRapa, under development for Familial Adenomatous Polyposis and Non-Muscle Invasive Blader Cancer; tolimidone, under development for the treatment of type 1 diabetes; and MTX110, which is being studied in aggressive rare\/orphan brain cancer indications.<\/p>\n<p align=\"justify\">eRapa is a proprietary oral tablet formulation of rapamycin, also known as sirolimus. Rapamycin is an mTOR (<u>m<\/u>ammalian <u>T<\/u>arget <u>O<\/u>f <u>R<\/u>apamycin) inhibitor. mTOR has been shown to have a significant role in the signalling pathway that regulates cellular metabolism, growth and proliferation and is activated during tumorigenesis.<\/p>\n<p align=\"justify\">Tolimidone is an orally delivered, potent and selective inhibitor of Lyn kinase. Lyn is a member of the Src family of protein tyrosine kinases, which is mainly expressed in hematopoietic cells, in neural tissues, liver, and adipose tissue. Tolimidone demonstrates glycaemic control via insulin sensitization in animal models of diabetes and has the potential to become a first in class blood glucose modulating agent.<\/p>\n<p align=\"justify\">MTX110 is a solubilized formulation of the histone deacetylase (HDAC) inhibitor, panobinostat. This proprietary formulation enables delivery of the product via convection-enhanced delivery (CED) at chemotherapeutic doses directly to the site of the tumor, by-passing the blood-brain barrier and potentially avoiding systemic toxicity.<\/p>\n<p align=\"justify\">Biodexa is supported by three proprietary drug delivery technologies focused on improving the bio-delivery and bio-distribution of medicines. Biodexa\u2019s headquarters and R&amp;D facility is in Cardiff, UK. For more information visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=BVFusNrQpMFq_eeclU-yKpCK5JXESZKyOwMhmnyn3jXr1aeZMbuOzc_GkDecdYi8Ko7kdB-bWdPGF5YOwHs9uAjxuwyZrQJFHRkNtvGIkdI=\" rel=\"nofollow\" target=\"_blank\">www.biodexapharma.com<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Forward-Looking Statements<\/strong><br \/>\n        <br \/>Certain statements in this announcement may constitute \u201cforward-looking statements\u201d within the meaning of legislation in the United Kingdom and\/or United States. Such statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and are based on management\u2019s belief or interpretation. All statements contained in this announcement that do not relate to matters of historical fact should be considered forward-looking statements. In certain cases, forward-looking statements can be identified by the use of words such as \u201cplans\u201d, \u201cexpects\u201d or \u201cdoes not anticipate\u201d, or \u201cbelieves\u201d, or variations of such words and phrases or statements that certain actions, events or results \u201cmay\u201d, \u201ccould\u201d, \u201cwould\u201d, \u201cmight\u201d or \u201cwill be taken\u201d, \u201coccur\u201d or \u201cbe achieved.\u201d Forward-looking statements and information are subject to various known and unknown risks and uncertainties, many of which are beyond the ability of the Company to control or predict, that may cause their actual results, performance or achievements to be materially different from those expressed or implied thereby, and are developed based on assumptions about such risks, uncertainties and other factors set out herein.<\/p>\n<p align=\"justify\">Reference should be made to those documents that Biodexa shall file from time to time or announcements that may be made by Biodexa in accordance with the rules and regulations promulgated by the SEC, which contain and identify other important factors that could cause actual results to differ materially from those contained in any projections or forward-looking statements. These forward-looking statements speak only as of the date of this announcement. All subsequent written and oral forward-looking statements by or concerning Biodexa are expressly qualified in their entirety by the cautionary statements above. Except as may be required under relevant laws in the United States, Biodexa does not undertake any obligation to publicly update or revise any forward-looking statements because of new information, future events or events otherwise arising.<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTA1MDEwMCM0MDIwNjUyNjEjMjI1OTMzMA==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml-eu.globenewswire.com\/media\/NGMwOWFiZmUtZmMxMy00YjJlLWE5MjYtYmExYTMxMDI2NmVmLTEyNzA4ODA=\/tiny\/Biodexa-Pharmaceuticals-PLC.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>February 24, 2025 Biodexa Announces Allowance of U.S. Patent Covering Oral Rapamycin Nanoparticle Preparations (\u201ceRapa\u201d) and Use Biodexa plans to initiate a Phase 3 registrational study of eRapa in Familial Adenomatous Polyposis (FAP) next quarter Biodexa Pharmaceuticals PLC (\u201cBiodexa\u201d or the \u201cCompany\u201d)(Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, today announced that the U.S. Patent and Trademark Office allowed has U.S. patent application No. 17\/391.495 titled \u201cOral Rapamycin Nanoparticle Preparations and Use\u201d which was exclusively licensed to Biodexa by Rapamycin Holdings, Inc. d\/b\/a Emtora Biosciences, along with other patents, in a transaction which closed in April 2024. The patent is due to issue on March 4, &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/biodexa-announces-allowance-of-u-s-patent-covering-oral-rapamycin-nanoparticle-preparations-erapa-and-use\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Biodexa Announces Allowance of U.S. Patent Covering  Oral Rapamycin Nanoparticle Preparations (\u201ceRapa\u201d) and Use&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-816772","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Biodexa Announces Allowance of U.S. Patent Covering Oral Rapamycin Nanoparticle Preparations (\u201ceRapa\u201d) and Use - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/biodexa-announces-allowance-of-u-s-patent-covering-oral-rapamycin-nanoparticle-preparations-erapa-and-use\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Biodexa Announces Allowance of U.S. Patent Covering Oral Rapamycin Nanoparticle Preparations (\u201ceRapa\u201d) and Use - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"February 24, 2025 Biodexa Announces Allowance of U.S. Patent Covering Oral Rapamycin Nanoparticle Preparations (\u201ceRapa\u201d) and Use Biodexa plans to initiate a Phase 3 registrational study of eRapa in Familial Adenomatous Polyposis (FAP) next quarter Biodexa Pharmaceuticals PLC (\u201cBiodexa\u201d or the \u201cCompany\u201d)(Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, today announced that the U.S. Patent and Trademark Office allowed has U.S. patent application No. 17\/391.495 titled \u201cOral Rapamycin Nanoparticle Preparations and Use\u201d which was exclusively licensed to Biodexa by Rapamycin Holdings, Inc. d\/b\/a Emtora Biosciences, along with other patents, in a transaction which closed in April 2024. The patent is due to issue on March 4, &hellip; Continue reading &quot;Biodexa Announces Allowance of U.S. Patent Covering Oral Rapamycin Nanoparticle Preparations (\u201ceRapa\u201d) and Use&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/biodexa-announces-allowance-of-u-s-patent-covering-oral-rapamycin-nanoparticle-preparations-erapa-and-use\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-02-24T15:39:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTA1MDEwMCM0MDIwNjUyNjEjMjI1OTMzMA==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biodexa-announces-allowance-of-u-s-patent-covering-oral-rapamycin-nanoparticle-preparations-erapa-and-use\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biodexa-announces-allowance-of-u-s-patent-covering-oral-rapamycin-nanoparticle-preparations-erapa-and-use\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Biodexa Announces Allowance of U.S. Patent Covering Oral Rapamycin Nanoparticle Preparations (\u201ceRapa\u201d) and Use\",\"datePublished\":\"2025-02-24T15:39:33+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biodexa-announces-allowance-of-u-s-patent-covering-oral-rapamycin-nanoparticle-preparations-erapa-and-use\\\/\"},\"wordCount\":1093,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biodexa-announces-allowance-of-u-s-patent-covering-oral-rapamycin-nanoparticle-preparations-erapa-and-use\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTA1MDEwMCM0MDIwNjUyNjEjMjI1OTMzMA==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biodexa-announces-allowance-of-u-s-patent-covering-oral-rapamycin-nanoparticle-preparations-erapa-and-use\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biodexa-announces-allowance-of-u-s-patent-covering-oral-rapamycin-nanoparticle-preparations-erapa-and-use\\\/\",\"name\":\"Biodexa Announces Allowance of U.S. Patent Covering Oral Rapamycin Nanoparticle Preparations (\u201ceRapa\u201d) and Use - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biodexa-announces-allowance-of-u-s-patent-covering-oral-rapamycin-nanoparticle-preparations-erapa-and-use\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biodexa-announces-allowance-of-u-s-patent-covering-oral-rapamycin-nanoparticle-preparations-erapa-and-use\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTA1MDEwMCM0MDIwNjUyNjEjMjI1OTMzMA==\",\"datePublished\":\"2025-02-24T15:39:33+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biodexa-announces-allowance-of-u-s-patent-covering-oral-rapamycin-nanoparticle-preparations-erapa-and-use\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biodexa-announces-allowance-of-u-s-patent-covering-oral-rapamycin-nanoparticle-preparations-erapa-and-use\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biodexa-announces-allowance-of-u-s-patent-covering-oral-rapamycin-nanoparticle-preparations-erapa-and-use\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTA1MDEwMCM0MDIwNjUyNjEjMjI1OTMzMA==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMTA1MDEwMCM0MDIwNjUyNjEjMjI1OTMzMA==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/biodexa-announces-allowance-of-u-s-patent-covering-oral-rapamycin-nanoparticle-preparations-erapa-and-use\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Biodexa Announces Allowance of U.S. Patent Covering Oral Rapamycin Nanoparticle Preparations (\u201ceRapa\u201d) and Use\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Biodexa Announces Allowance of U.S. Patent Covering Oral Rapamycin Nanoparticle Preparations (\u201ceRapa\u201d) and Use - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/biodexa-announces-allowance-of-u-s-patent-covering-oral-rapamycin-nanoparticle-preparations-erapa-and-use\/","og_locale":"en_US","og_type":"article","og_title":"Biodexa Announces Allowance of U.S. Patent Covering Oral Rapamycin Nanoparticle Preparations (\u201ceRapa\u201d) and Use - Market Newsdesk","og_description":"February 24, 2025 Biodexa Announces Allowance of U.S. Patent Covering Oral Rapamycin Nanoparticle Preparations (\u201ceRapa\u201d) and Use Biodexa plans to initiate a Phase 3 registrational study of eRapa in Familial Adenomatous Polyposis (FAP) next quarter Biodexa Pharmaceuticals PLC (\u201cBiodexa\u201d or the \u201cCompany\u201d)(Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs, today announced that the U.S. Patent and Trademark Office allowed has U.S. patent application No. 17\/391.495 titled \u201cOral Rapamycin Nanoparticle Preparations and Use\u201d which was exclusively licensed to Biodexa by Rapamycin Holdings, Inc. d\/b\/a Emtora Biosciences, along with other patents, in a transaction which closed in April 2024. The patent is due to issue on March 4, &hellip; Continue reading \"Biodexa Announces Allowance of U.S. Patent Covering Oral Rapamycin Nanoparticle Preparations (\u201ceRapa\u201d) and Use\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/biodexa-announces-allowance-of-u-s-patent-covering-oral-rapamycin-nanoparticle-preparations-erapa-and-use\/","og_site_name":"Market Newsdesk","article_published_time":"2025-02-24T15:39:33+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTA1MDEwMCM0MDIwNjUyNjEjMjI1OTMzMA==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biodexa-announces-allowance-of-u-s-patent-covering-oral-rapamycin-nanoparticle-preparations-erapa-and-use\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biodexa-announces-allowance-of-u-s-patent-covering-oral-rapamycin-nanoparticle-preparations-erapa-and-use\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Biodexa Announces Allowance of U.S. Patent Covering Oral Rapamycin Nanoparticle Preparations (\u201ceRapa\u201d) and Use","datePublished":"2025-02-24T15:39:33+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biodexa-announces-allowance-of-u-s-patent-covering-oral-rapamycin-nanoparticle-preparations-erapa-and-use\/"},"wordCount":1093,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biodexa-announces-allowance-of-u-s-patent-covering-oral-rapamycin-nanoparticle-preparations-erapa-and-use\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTA1MDEwMCM0MDIwNjUyNjEjMjI1OTMzMA==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biodexa-announces-allowance-of-u-s-patent-covering-oral-rapamycin-nanoparticle-preparations-erapa-and-use\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/biodexa-announces-allowance-of-u-s-patent-covering-oral-rapamycin-nanoparticle-preparations-erapa-and-use\/","name":"Biodexa Announces Allowance of U.S. Patent Covering Oral Rapamycin Nanoparticle Preparations (\u201ceRapa\u201d) and Use - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biodexa-announces-allowance-of-u-s-patent-covering-oral-rapamycin-nanoparticle-preparations-erapa-and-use\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biodexa-announces-allowance-of-u-s-patent-covering-oral-rapamycin-nanoparticle-preparations-erapa-and-use\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTA1MDEwMCM0MDIwNjUyNjEjMjI1OTMzMA==","datePublished":"2025-02-24T15:39:33+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biodexa-announces-allowance-of-u-s-patent-covering-oral-rapamycin-nanoparticle-preparations-erapa-and-use\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/biodexa-announces-allowance-of-u-s-patent-covering-oral-rapamycin-nanoparticle-preparations-erapa-and-use\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biodexa-announces-allowance-of-u-s-patent-covering-oral-rapamycin-nanoparticle-preparations-erapa-and-use\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTA1MDEwMCM0MDIwNjUyNjEjMjI1OTMzMA==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMTA1MDEwMCM0MDIwNjUyNjEjMjI1OTMzMA=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/biodexa-announces-allowance-of-u-s-patent-covering-oral-rapamycin-nanoparticle-preparations-erapa-and-use\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Biodexa Announces Allowance of U.S. Patent Covering Oral Rapamycin Nanoparticle Preparations (\u201ceRapa\u201d) and Use"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/816772","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=816772"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/816772\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=816772"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=816772"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=816772"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}